Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Large Volume Increase – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) shares saw an uptick in trading volume on Thursday . 410,384 shares were traded during mid-day trading, an increase of 77% from the previous session’s volume of 231,787 shares.The stock last traded at $23.15 and had previously closed at $23.28.

Wall Street Analyst Weigh In

Several research firms have weighed in on CHGCY. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Chugai Pharmaceutical presently has a consensus rating of “Buy”.

Get Chugai Pharmaceutical alerts:

View Our Latest Research Report on Chugai Pharmaceutical

Chugai Pharmaceutical Stock Performance

The firm’s 50-day simple moving average is $25.81 and its two-hundred day simple moving average is $27.23. The stock has a market cap of $76.11 billion, a price-to-earnings ratio of 25.69 and a beta of 0.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its quarterly earnings results on Friday, April 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. The company had revenue of $2.05 billion during the quarter. Equities research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.

Featured Articles

• Five stocks we like better than Chugai Pharmaceutical
• The World Cup Is Coming—These 3 Stocks Could Cash In
• Spotify’s “North Star” Outlook Was Music to Investors Ears
• Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
• Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.